Company

4D Molecular Therapeutics, Inc.

Headquarters: EmeryVille, CA, United States

Employees: 121

CEO: Dr. David H. Kirn

NASDAQ: FDMT +0.23%

Market Cap

$837.5 Million

USD as of Jan. 1, 2024

Market Cap History

4D Molecular Therapeutics, Inc. market capitalization over time

Evolution of 4D Molecular Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of 4D Molecular Therapeutics, Inc.

Detailed Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

4D Molecular Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: FDMT wb_incandescent

Details

Headquarters:

5858 Horton Street

Suite 455

EmeryVille, CA 94608

United States

Phone: 510-505-2680